Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Franklin Resources, Inc. (BEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Franklin Resources, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.2 (market cap $29.60B), while Franklin Resources, Inc. trades at $33.49 (market cap $16.95B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Franklin Resources, Inc. pays a 3.96% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BEN | |
|---|---|---|
Market Cap | $29.60B | $16.95B |
Sector | Health | Financials |
52-Week High | $491.22 | $35.77 |
52-Week Low | $205.48 | $21.18 |
Enterprise Value | $27.56B | $29.90B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Franklin Resources (BEN) trades at $33.56, up 0.12% on the day, with a bullish technical signal and consistent earnings beats. The company reported record AUM of $1.80 trillion as of July 31, 2026, driven by strong inflows and diversification efforts. Valuation ratios include a P/E of 22.69 and P/S of 1.85, while profitability shows a net income margin of 8.72%.
The outlook is positive with analyst consensus price target of $36.50, though risks include volatile cash flows and competitive pressures. Upside potential hinges on sustained AUM growth and margin expansion, while investor sentiment is mixed with 59% hold ratings amid recent institutional selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →
